Conditions: Central Precocious Puberty
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 44
Healthy volunteers: no

Brief summary:
The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg 6-month formulation in 44 patients suffering from central precocious puberty. The total study duration per patient will be 12 months (48 weeks).

Detailed description:

Arms:
arm 1: Triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169

Interventions: intervention 1: Triptorelin
Intervention descriptions: intervention 1: Powder and solution for solution for injection

Protocol document: